Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer | Zendy

Andrew Jallouk | Zendy; Sriram S. Paravastu | Zendy; Katherine N. Weilbaecher | Zendy; Rebecca Aft | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer

Author(s) -

Andrew Jallouk,

Sriram S. Paravastu,

Katherine N. Weilbaecher,

Rebecca Aft

Publication year - 2021

Publication title -

breast cancer research and treatment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.908

H-Index - 154

eISSN - 1573-7217

pISSN - 0167-6806

DOI - 10.1007/s10549-021-06100-2

Subject(s) - medicine , zoledronic acid , breast cancer , chemotherapy , oncology , population , bisphosphonate , cancer , osteoporosis , environmental health

The role of zoledronic acid (ZOL), a bone-targeted bisphosphonate, in the treatment of patients with breast cancer remains an active area of study. Here, we report the long-term outcomes of a randomized placebo-controlled phase II clinical trial in which ZOL treatment was added to neoadjuvant chemotherapy in women with locally advanced breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research